{"nctId":"NCT01299389","briefTitle":"An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia","startDateStruct":{"date":"2010-10"},"conditions":["Schizophrenia"],"count":323,"armGroups":[{"label":"Paliperidone palmitate","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone palmitate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Paliperidone palmitate","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants meeting Diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision\n* Women had to be: postmenopausal (for at least 2 years), surgically sterile (had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (as judged by the investigator; per local regulations), or if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method \\[eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel\\], male partner sterilization) as local regulations permitted, before entry, and had to agree to continue to use the same method of contraception throughout the study\n* A Positive and Negative Syndrome Scale (PANSS) total score at screening and at baseline (Day 1) of 60 to 120\n* Documented history of exposure to either a risperidone formulation or a paliperidone formulation and known to be tolerated before baseline (Day 1) (Even if the participant's experience of taking risperidone or paliperidone cannot be confirmed at the time of informed consent, the participant will be able to meet this criterion if the participant takes oral risperidone 2 mg/day or more or paliperidone ER 6 mg/day or more for at least 4 days between the day of informed consent and the day before baseline, and it is possible to confirm that there is no lack of tolerability in the participant)\n* Women of childbearing potential must have a negative beta human chorionic gonadotropin pregnancy test at the screening urine pregnancy test\n\nExclusion Criteria:\n\n* Primary active Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision Axis I diagnosis other than schizophrenia\n* A Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)\n* Relevant history or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease\n* History or current presence of neuroleptic malignant syndrome or tardive dyskinesia\n* Known or suspected hypersensitivity or intolerance to risperidone, paliperidone, Intralipid, or any of their excipients (including egg yolks, soybean oil, phospholipids, and glycerol)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation","description":"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":"15.18"},{"groupId":"OG001","value":"85.7","spread":"14.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"19.13"},{"groupId":"OG001","value":"-3.1","spread":"20.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation","description":"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\", higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Response to the Treatment as Per PANSS Total Score.","description":"Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation","description":"The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":"5.56"},{"groupId":"OG001","value":"24.2","spread":"5.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"6.06"},{"groupId":"OG001","value":"-1.1","spread":"6.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":"6.22"},{"groupId":"OG001","value":"22.8","spread":"6.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"5.82"},{"groupId":"OG001","value":"-1.4","spread":"5.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"5.13"},{"groupId":"OG001","value":"20.8","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"5.24"},{"groupId":"OG001","value":"-0.6","spread":"5.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"3.07"},{"groupId":"OG001","value":"8.6","spread":"3.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"4.23"},{"groupId":"OG001","value":"0.4","spread":"4.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"3.02"},{"groupId":"OG001","value":"9.4","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"3.27"},{"groupId":"OG001","value":"-0.4","spread":"3.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation","description":"Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"6.19"},{"groupId":"OG001","value":"24.0","spread":"5.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"5.54"},{"groupId":"OG001","value":"-1.5","spread":"5.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation","description":"Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"4.97"},{"groupId":"OG001","value":"19.5","spread":"5.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"5.82"},{"groupId":"OG001","value":"-0.6","spread":"6.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation","description":"General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":"7.97"},{"groupId":"OG001","value":"42.3","spread":"7.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"10.32"},{"groupId":"OG001","value":"-1.0","spread":"11.04"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":164},"commonTop":["Insomnia","Nasopharyngitis","Psychiatric symptom","Constipation","Injection site pain"]}}}